Abstract
Background: Although the clinical benefit of interleukin-2-receptor antibody (IL-2RAb) induction in reducing the risk of acute rejection in adult kidney transplant recipients is well established, a similar benefit in paediatric recipients remains controversial. The aim of this study is to evaluate the efficacy of IL-2RAb in reducing acute rejection in paediatric and adolescent recipients aged
Original language | English |
---|---|
Pages (from-to) | 2146-2151 |
Number of pages | 6 |
Journal | Transplantation |
Volume | 101 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sept 2017 |